BiologicalDrug
6 Melanoma Helper Peptide Vaccine clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2016 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 3
Craig L Slingluff, Jr (2) · University of Virginia (1)
Often tested with
Tested in the same studies.
CDX-1140 (1) · Incomplete Freund's adjuvant (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · BRAF Inhibitor (1) · Mitogen-Activated Protein Kinase Kinase Inhibitor (1)
Studies
Open first, then newest update. How each study uses 6 Melanoma Helper Peptide Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 3
- Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)CompletedPhase 1/2Craig L Slingluff, JrNCT04364230Written as 6MHP
- A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibTerminatedEarly Phase 1Craig L Slingluff, JrNCT02382549Written as 6MHP
- Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV MelanomaCompletedPhase 1/2University of VirginiaNCT00089219Written as 6MHP
Given in every arm · 4 — 6 Melanoma Helper Peptide Vaccine is usual care beside what is tested
- Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaCompletedPhase 1/2Craig L Slingluff, JrNCT03617328Written as 6MHP
- Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of MelanomaTerminatedPhase 1/2Craig L Slingluff, JrNCT02425306Written as 6MHP
- Safety Study of a Helper Peptide Vaccine Plus PembrolizumabCompletedPhase 1/2Craig L Slingluff, JrNCT02515227Written as 6MHP
- A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With MelanomaTerminatedPhase 1/2Craig L Slingluff, JrNCT02385669Written as 6MHP